Research Topics
| K Alexander PappSummaryAffiliation: Probity Medical Research Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasisKim A Papp
Probity Medical Research, Waterloo, Ontario, Canada
J Am Acad Dermatol 48:48-54. 2003..A new vehicle has been created with the objective of obtaining optimal stability of both calcipotriene and betamethasone dipropionate in the combination product...
The long-term efficacy and safety of new biological therapies for psoriasisKim A Papp
Probity Medical Research, University of Western Ontario, 135 Union Street East, Waterloo, Ontario, Canada
Arch Dermatol Res 298:7-15. 2006..Long-term data from psoriasis trials continue to accumulate. Recent data suggest that biological therapies have efficacy and safety profiles suitable for the long-term treatment of patients with moderate to severe psoriasis...- Efalizumab for the treatment of psoriatic arthritisKim A Papp
Probity Medical Research, Waterloo, ON, Canada
J Cutan Med Surg 11:57-66. 2007..The effect of efalizumab therapy on PsA has not previously been investigated... - Psoriasis care: new and emerging pharmacologic trendsKim A Papp
Probity Medical Research, Waterloo, ON
J Cutan Med Surg 14:119-29. 2010..The guidelines advocate patient-centered psoriasis care in which physicians explore appropriate options to find safe therapies that patients will adhere to and be satisfied with over the long term... 
Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging studyK A Papp
Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada
Br J Dermatol 167:668-77. 2012..Tofacitinib is a novel, oral Janus kinase inhibitor under investigation as a potential treatment for plaque psoriasis...- Efficacy and safety of adalimumab when added to inadequate therapy for the treatment of psoriasis: results of PRIDE, an open-label, multicentre, phase IIIb studyK Papp
Probity Medical Research, Waterloo, ON, Canada
J Eur Acad Dermatol Venereol 26:1007-13. 2012..Adalimumab is an effective treatment for chronic plaque psoriasis... - Biologic therapy in psoriasis: perspectives on associated risks and patient managementKim A Papp
Probity Medical Research, Waterloo, ON
J Cutan Med Surg 16:153-68. 2012..Previous publications have described practical considerations for initiating biologic therapy in psoriasis patients. However, most publications have focused on anti-tumor necrosis factor (TNF) therapy... - Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trialKim Papp
Probity Medical Research, Waterloo, ON, Canada
Lancet 380:738-46. 2012..We assessed the clinical efficacy and safety of different doses of apremilast in the treatment of patients with moderate to severe plaque psoriasis... - Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adultsKim A Papp
Probity Medical Research Inc, Waterloo, Ontario, Canada
J Am Acad Dermatol 67:e11-5. 2012..Tacrolimus is a topical calcineurin inhibitor with immunomodulatory, anti-inflammatory, and fungicidal properties that may be beneficial in the treatment of facial seborrheic dermatitis... - Brodalumab, an anti-interleukin-17-receptor antibody for psoriasisKim A Papp
Probity Medical Research, Waterloo, ON, Canada
N Engl J Med 366:1181-9. 2012.... - Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case seriesMichelle A Lowes
Laboratory for Investigative Dermatology, The Rockefeller University, New York, New York, USA
BMC Dermatol 7:2. 2007..Newer biological therapies for moderate-to-severe psoriasis are being used more frequently, but unexpected effects may occur... - Monitoring patients treated with efalizumab or alefaceptK A Papp
Probity Medical Research, Waterloo, ON, Canada
Curr Probl Dermatol 38:95-106. 2009..Most important for patients on either therapy is appropriate intermittent clinical evaluations to ensure stable, safe, and effective therapy... - Monitoring biologics for the treatment of psoriasisKim A Papp
Probity Medical Research, University of Western Ontario, 135 Union Street East, Waterloo, ON, Canada N2J 1C4
Clin Dermatol 26:515-21. 2008..The better risks and benefits are understood, the more precise monitoring guidelines can be defined... 
Analytical approaches to reporting long-term clinical trial dataKim A Papp
Probity Medical Research, Waterloo, ON, Canada
Curr Med Res Opin 24:2001-8. 2008..Therefore, standard analytical strategies used in short-term randomized, controlled trials (intent-to-treat, per-protocol) may not always be appropriate for data generated in long-term studies...- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)Kim A Papp
Probity Medical Research, Waterloo and University of Western Ontario, London, ON, Canada
Lancet 371:1675-84. 2008..This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in partial responders... - Adalimumab in the treatment of psoriasis: pooled efficacy and safety results from three pivotal studiesKim Papp
Probity Medical Research, University of Western Ontario, Waterloo, ON
J Cutan Med Surg 13:S58-66. 2009..Adalimumab, a fully human monoclonal antibody, binds to and neutralizes tumor necrosis factor... - Epidemiology of moderate-to-severe plaque psoriasis in a Canadian surveyed populationKim Papp
K Papp Clinical Research, Probity Medical Research, Waterloo, ON
J Cutan Med Surg 14:167-74. 2010..limited data are available on the epidemiologic features of psoriasis in Canada... - Clinical development of onercept, a tumor necrosis factor binding protein, in psoriasisKim Papp
Probity Medical Research Inc, Waterloo, Ontario, Canada
Curr Med Res Opin 26:2287-300. 2010..Tumor necrosis factor (TNF)-α plays a critical role in psoriasis pathogenesis, and several anti-TNF agents have been developed as therapeutic drugs in this indication... - Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trialsKim A Papp
Probity Medical Research, Waterloo, Ontario, Canada
Clin Drug Investig 31:51-60. 2011..Rates and impacts of worsening symptoms in patients with psoriasis have not been well characterized... - Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapyK Papp
Probity Medical Research, Waterloo, ON, Canada
Br J Dermatol 164:434-41. 2011..Adalimumab is effective for moderate to severe chronic plaque psoriasis; however, data regarding retreatment following withdrawal and subsequent relapse are limited... - Canadian guidelines for the management of plaque psoriasis: overviewKim Papp
K Papp Clinical Research, Waterloo, ON, Canada
J Cutan Med Surg 15:210-9. 2011..dermatology.ca/guidelines/cdnpsoriasisguidelines.pdf> (English) or <http://www.dermatology.ca/french/psoriasisguidelines.html> (French)... - Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III studyK Papp
Probity Medical Research, Waterloo, ON, Canada
Lancet 371:1337-42. 2008..ISA247, a novel inhibitor, was effective and well tolerated in a phase II study of patients with plaque psoriasis. Therefore its efficacy was assessed in this phase III study... - Scalp psoriasis: a review of current topical treatment optionsK Papp
Probity Medical Research Union, Waterloo, Ontario, Canada
J Eur Acad Dermatol Venereol 21:1151-60. 2007.... - Etanercept in psoriasisKim A Papp
Probity Medical Research, 135 Union Street East, Waterloo, ON N2J 1C4, Canada
Expert Opin Pharmacother 5:2139-46. 2004..No opportunistic infections, including tuberculosis, were reported. From analysis of the available clinical trials, etanercept appears to be an effective and well-tolerated agent for the treatment of moderate-to-severe psoriasis... - Efalizumab: Advancing psoriasis management with a novel, targeted T-cell modulatorKim A Papp
Probity Medical Research, Waterloo, Ontario, Canada
Drugs Today (Barc) 40:889-99. 2004..This article reviews the role of T lymphocytes in psoriasis pathogenesis, the mechanism of efalizumab action, and the efficacy and safety data observed during the efalizumab clinical trials... - Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year studyKim A Papp
Probity Medical Research, Hannover Medical University, Waterloo, Ontario, Canada
J Am Acad Dermatol 52:240-6. 2005..Pimecrolimus was applied twice daily at the first signs or symptoms of the disease until clearance. Outcome measures included the incidence of adverse events and the Eczema Area and Severity Index (EASI)... - Long-term treatment of atopic dermatitis with pimecrolimus cream 1% in infants does not interfere with the development of protective antibodies after vaccinationKim A Papp
Probity Medical Research, Waterloo, Ontario, Canada
J Am Acad Dermatol 52:247-53. 2005..We investigated whether treatment of atopic dermatitis with pimecrolimus cream 1% in infants affects the development of a normal antibody response to vaccinations... - Potential future therapies for psoriasisK Alexander Papp
Probity Medical Research, and University of Western Ontario, London, Ontario, Canada
Semin Cutan Med Surg 24:58-63. 2005 - A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reductionK A Papp
Probity Medical Research, Waterloo, Ontario N2J 1C4, Canada
Br J Dermatol 152:1304-12. 2005..In previous studies, etanercept significantly improved plaque psoriasis and was well tolerated... - Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasisKim A Papp
Probity Medical Research, Waterloo, Ontario, Canada
J Am Acad Dermatol 54:S164-70. 2006..Efalizumab targets T cell-mediated steps important in psoriasis immunopathogenesis... - Strategies for optimizing treatment with efalizumab in moderate to severe psoriasisKim A Papp
Probity Medical Research, N2J 1B7, Waterloo, ON
J Cutan Med Surg 9:26-32. 2006..A growing body of clinical evidence, as well as experience from clinical investigators, has provided much insight into the management strategies for patients undergoing treatment with efalizumab... - Safety of efalizumab in patients with moderate to severe chronic plaque psoriasis: review of clinical data. part IIKim A Papp
University of Western Ontario, Waterloo, Ont, Canada
J Cutan Med Surg 9:313-23. 2005..The efficacy and safety of efalizumab have been evaluated in multiple clinical trials... - Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trialKim A Papp
Probity Medical Research, Waterloo, Ontario, Canada
Int J Dermatol 45:605-14. 2006..To provide safety data for efalizumab, a recombinant humanized monoclonal IgG(1) antibody, in adults with chronic plaque psoriasis... - Evaluation of efalizumab using safe psoriasis controlKim A Papp
Probity Medical Research, 135 Union Street East, Waterloo, Ontario, Canada
BMC Dermatol 6:8. 2006.... - Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrenceKim A Papp
Probity Medical Research, Waterloo, and University of Western Ontario, Ontario, Canada
BMC Dermatol 6:9. 2006..This analysis evaluated approaches for managing inflammatory recurrence after discontinuation of efalizumab... - The treatment of moderate to severe psoriasis with a new anti-CD11a monoclonal antibodyK Papp
Probity Medical Research, 30 Union St East, Waterloo, Ontario N2J 1B7, Canada
J Am Acad Dermatol 45:665-74. 2001..This study investigated whether treatment with anti-CD11a antibody provides clinical benefit to patients with moderate to severe plaque psoriasis... - Safe psoriasis control: a new outcome measure for the composite assessment of the efficacy and safety of psoriasis treatmentKim A Papp
Probity Medical Research, Waterloo, Ontario, Canada
J Cutan Med Surg 9:276-83. 2005..CONCLUSION: The SPC endpoint may be a step-forward in providing a composite tool for the evaluation of treatments for psoriasis...